# Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

> **NCT03382587** · — · COMPLETED · sponsor: **Bayer** · enrollment: 163 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT03382587
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-05
- **Primary completion:** 2018-11-09
- **Final completion:** 2018-11-27
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382587, "Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03382587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*